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tamoxifen from a German health service perspective. METHODS: A semi-Markov 
model was adapted to include the 100-month clinical trial efﬁcacy data. Kaplan-Meier 
curves on time to recurrence (TTR) from the ATAC trial were ﬁtted by survival regres-
sion including a treatment coefﬁcient. Treatment speciﬁc progression rates were 
extrapolated to 10 years, and were assumed equivalent based on pooled treatment 
arms thereafter. Survival probabilities after recurrence were identical for all treat-
ments, based on German national mortality data. Published literature and physician 
survey provided data on resource use and unit costs and utilities. Probabilistic analysis 
was carried out to obtain incremental cost-effectiveness ratios and cost-effectiveness 
acceptability curves. Sensitivity analyses were conducted. RESULTS: Over 25 years 
anastrozole patients gained 0.32 QALYs at a cost of a6,819 per patient, resulting in 
an ICER of a21,069 (95%CI: a12,567–a46,604) per QALY gained, vs tamoxifen. 
With a 90% probability the ICER was below a30,000/QALY. The results were 
robust to plausible changes in parameters tested in sensitivity analyses, including the 
hazard ratio for TTR. CONCLUSIONS: This is the ﬁrst cost-utility analysis of an 
aromatase inhibitor based on extended follow-up data. Anastrozole’s carryover 
treatment effect beyond therapy completion at 5 years translates into favourable 
cost-effectiveness results against tamoxifen for PM HR EBC women from a German 
national health insurance perspective.
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OBJECTIVES: To evaluate cost-utility of docetaxel (75 mg/m2 every 3 weeks) com-
pared with best supportive care (BSC) or pemetrexed (500 mg/m2 every 3 weeks) as 
second-line therapy in advanced non-small cell lung cancer in the Polish setting. 
METHODS: A cost-utility approach was adopted, evaluating total direct costs 
incurred by the Polish National Health Fund (NHF), life years gained (LYG) and 
quality-adjusted life years (QALY). A micro-simulation Markov model was used to 
estimate utilities and costs of treatment. The ﬁrst course of chemotherapy was assumed 
as the starting-time point of the model. Simulation was terminated at the time of the 
patient’s death or after two years following start of the treatment. It was assumed that 
patients would undergo 4 cycles of chemotherapy or less if progression occurred 
during treatment. In case of progression of disease chemotherapy would be terminated 
and patients would receive palliative care until death. Transition probabilities between 
health states were calculated based on a systematic review of RCTs. Health states 
utilities were taken from published literature. Costs were taken from NHF catalogue. 
Probabilistic sensitivity analysis was performed in order to estimate the probability 
that docetaxel was cost effective in Polish settings where threshold is about 91,000 
polish zloty (PLN). RESULTS: Incremental costs for docetaxel compared with BSC 
was PLN57,498 per LYG and PLN105,956 per QALY. In 2-years time horizon 
docetaxel was PLN13,582 less costly than pemetrexed (CI95%: 8,224; 17,704). The 
probability of docetaxel cost effectiveness over BSC was 99.71% for LYG and 10.11% 
for QALY. The probability of docetaxel cost effectiveness over pemetrexed was 
99.78% for LYG and 100% for QALY. CONCLUSIONS: Docetaxel seems to be cost 
effective in comparison with BSC and pemetrexed in the Polish setting.
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OBJECTIVES: More than one million new cases of colorectal cancer are diagnosed 
worldwide annually. In Ireland, incidence rates are among the highest in western 
Europe, survival is lower than the European average, and mortality in men exceeds 
that in other western European countries. We evaluated the cost-effectiveness of a 
population-based colorectal cancer screening programme in Ireland. METHODS: 
Three screening scenarios were assessed: 1) biennial guaiac-based faecal occult blood 
testing (gFOBT) in those aged 55–74; 2) biennial faecal immunochemical testing (FIT) 
in those aged 55–74; and 3) once-only ﬂexible sigmoidoscopy (FSIG) at age 60. A 
Markov model was used to followed a cohort of 55-year-old individuals over their 
lifetime. Model parameters were obtained from local data, literature review and expert 
clinical opinion. Costs included screening and diagnostic tests, cancer treatment, 
complications, and surveillance of screen-detected adenomas. Health outcomes were 
assessed in quality-adjusted life years (QALYs). Costs and outcomes were discounted 
at 4% per annum. Screening scenarios were compared with the status quo (“no screen-
ing”). Probabilistic sensitivity analyses were undertaken. RESULTS: All three screen-
ing scenarios were highly cost-effective compared to no screening. In the base-case 
analysis, FSIG had the lowest incremental cost-effectiveness ratio (ICER  a589 per 
QALY gained), followed by FIT (a1,696 per QALY gained), and gFOBT (a4428 per 
QALY gained). gFOBT was dominated. Compared to FSIG, FIT was associated with 
a greater health gain, and greater lifetime reductions in colorectal cancer incidence 
(15%) and mortality (36%). However, it was more costly than FSIG, required more 
colonoscopies, and would result in more complications. The ICER for FIT versus FSIG 
was a2058 per QALY gained. Results were robust to variations in parameter esti-
mates. CONCLUSIONS: These results suggest that population-based colorectal cancer 
screening would be a highly cost-effective in Ireland. FIT is the optimal screening 
strategy since it as associated with the greatest health gain.
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OBJECTIVES: Prostatic cancer is the second most frequent cancer and the third 
highest cause of cancer-related deaths in Italy. Age is the principal risk factor and 
given the ageing Italian population, it seems that the related health care expenditure 
is bound to increase, causing the need for pharmacoeconomic evaluation of therapies 
available. METHODS: We performed a cost/utility analysis using a Markov model of 
hormonal therapies in patients with advanced prostate cancer who underwent radical 
prostatectomy, from biochemical recurrence to death. Nine androgen suppression 
therapies were considered: orchiectomy, two nonsteroidal antiandrogens (NSAA), four 
luteinising hormone-releasing hormone (LHRH) agonists, cyproterone acetate and the 
maximal androgen blockade (MAB) obtained with the association of a NSAA and a 
LHRH. In the simulation, the androgen suppression therapies were started at PSA 
recurrence and continued until death. The model used the Italian NHS prospective 
and a patient’s lifetime simulation horizon. Drug costs were calculated for each 
therapy, considering the less costly brand. RESULTS: All therapies produced a life 
expectancy (LE) of about 12 life years (LYs) with a small variability ranging from 
12.3 LYs for MAB to 11.37 LYs for NSAA-ﬂutamide. Quality adjusted life expectancy 
ranged from 9.98 QALYs for MAB to 9.28 QALYs for NSAA-ﬂutamide. The cost per 
patient presented more variability, from a12,538 for orchiectomy to a59,496 for 
NSAA-bicalutamide. Orchiectomy provided the most cost/effective alternative with 
a1300/QALY. In the LHRH-agonists class leuprorelin was the most cost/effective at 
about a2200/QALY. CONCLUSIONS: MAB was identiﬁed as the most effective and 
the most costly therapy. Orchiectomy was less effective but involved the lowest cost 
and, thus, represented the most cost/effective strategy. Nonetheless, its application in 
actual clinical practice is difﬁcult and it is almost always refused by patients. Among 
the class of LHRH-agonists, leuprorelin (22.5 mg–7.5 mg) dominated the alternatives 
and provided an excellent therapeutic strategy.
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OBJECTIVES: At a median follow-up of 100 months in the ATAC trial, anastrozole 
demonstrated signiﬁcant improvements compared with tamoxifen in disease-free sur-
vival (HR: 0.85, p  0.003) and time-to recurrence (TTR) (HR: 0.76, p  0.0001). 
Absolute difference in TTR increased over time, 2.8% at 5 years and 4.8% at 9 years. 
Recurrence rates remained signiﬁcantly lower on anastrozole after treatment comple-
tion. This study assesses the long-term cost-effectiveness of adjuvant treatment 
with anastrozole versus tamoxifen in women with early breast cancer in Sweden. 
METHODS: A Markov model was developed to integrate trial data with external 
data on costs and quality of life speciﬁc for Swedish breast cancer patients. The model 
adopts a life-long perspective and the primary outcome measure was QALYs. In the 
base-case model, TTR for tamoxifen and anastrozole diverge out to 10 years. Mortal-
ity risks for recurred and non-recurred patients are based upon trial data and national 
statistics. Resource utilization and utility estimates were based on Swedish data for 
patients in different stages of breast cancer. Utility weights were estimated with EQ-
5D. All costs and beneﬁts were discounted at 3% at 2005-year prices. RESULTS: 
In base-case, patients treated with anastrozole had a higher lifetime expected mean 
cost of SEK 16,000 compared to patients on tamoxifen, and gained on average 0.11 
QALYs per patient. This corresponds to an incremental cost of approximately SEK 
145,000 per QALY gained. CONCLUSIONS: This updated cost-effectiveness analysis 
of the ATAC trial is conservative, neither is any assumption made of an accrued sur-
vival beneﬁt due to a signiﬁcantly lower recurrence rate, nor does the analysis consider 
the potential reduction of costs associated with anastrozole patent expiry. Neverthe-
less, the study demonstrates that up-front anastrozole treatment for ﬁve years is a 
cost-effective option compared to ﬁve years tamoxifen treatment in the lifetime per-
spective for hormone receptor-positive patients.
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OBJECTIVES: The Brazilian guideline for the treatment of CML is not clear whether 
to increase imatinib dosage or switch to dasatinib for imatinib-resistant patients. The 
aim of this study was to evaluate the value of dasatinib versus imatinib 400 mg for 
treatment of imatinib-resistant CML patients (dasatinib 100 mg vs. imatinib 600 mg 
for CP and dasatinib 140 mg vs. imatinib 800 mg for AP and BP), from the Brazilian 
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Health Care System (SUS) perspective. We also studied the value of dasatinib versus 
nilotinib. METHODS: A cost-utility lifetime Markov model was developed to calcu-
late the incremental cost per Quality-Adjusted Life Year (QALY). Disease progression 
depended on the best treatment response rates taken from dasatinib clinical trials. 
Transition probabilities and utilities were estimated from published literature. Drugs 
costs were obtained according to ofﬁcial prices and standard government discounting 
procedures. Since nilotinib does not have a published price in Brazil, the lowest inter-
national price found on the internet was used. Resource utilization was based on 
clinical survey. Both costs and effects were discounted annually at 5.0%. The robust-
ness of the results was assessed through deterministic and probabilistic sensitivity 
analysis. RESULTS: In the base case, lifetime treatment resulted in dominance of 
dasatinib in CP versus both imatinib 400 mg and nilotinib, and an incremental cost-
effectiveness ratio (ICER) of about a52,000/QALY for AP and approximately 
a51,000/QALY for BP against imatinib. Sensitivity analysis showed pharmaceutical 
costs as the most important driver of the result. CONCLUSIONS: Compared to 
 imatinib 400 mg and nilotinib, dasatinib is associated with increased QALYs in all 
phases and lower overall costs in CP. So dasatinib is the dominant strategy for the 
treatment of chronic phase CML patients who are resistant to imatinib. Since clinical 
outcomes for imatinib 800 mg for advanced phases are unsatisfactory, dasatinib 
140 mg is a reasonable option for imatinib-resistant CML patients in accelerated and 
blast phases.
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OBJECTIVES: The costs of second line treatment for non small cell lung cancer 
(NSCLC) has dramatically increased during the last decade. The objective of this phase 
III, randomized, multicenter study was to compare from the payer’s perspective the 
economical impact of two widely used treatments: pemetrexed versus docetaxel. 
METHODS: This study included progressive NSCLC: docetaxel 75 mg/m2 (arm A) 
versus pemetrexed 500 mg/m2 (arm B) every three weeks. The number of subjects 
was determined to ﬁnd a second line direct cost difference of 10% between the two 
arms (A  0.05, B  0.20). The analysis recorded: transportation, drug, administration 
(outpatient or inpatient) and adverse events costs. Average and 95% conﬁdence 
intervals, cost-differences were calculated by non parametric methods (bootstrap, SAS 
software). RESULTS: 150 patients were enrolled between February 2006 and June 
2008. There were no differences between the two arms in terms of sex, age, performans 
status, weight loss, body surface, history. TTP was 2.8 m [2.26–4.23] for arm A, 
2.53 m [2.16–4.00] for arm B (p  0.85). The mean number of cycles was 3.7 (o 1.9) 
for arm A and 3.6 (o 1.75) for arm B. There were no differences for overall toxicities 
(p  0.55), and for grade 1–2 toxicities. In the opposite, there was a signiﬁcantly dif-
ference in term of overall grade 3–4 toxicities: 39/75 for arm A (52%) versus 25/75 
(33%) for arm B (p  0.02). In terms of chemotherapy costs, arm B was more costly: 
a777,082.76 versus a513,700.42 (51%). In terms of global costs, the difference was 
decreased at 37%. CONCLUSIONS: Chemotherapy with pemetrexed was more 
expansive for 2d line NSCLC treatment. The difference decreased according to adverse 
events and administration costs. Cost-effectiveness and sensitivity analyses will be 
presented at the meeting.
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OBJECTIVES: We analyzed the impact of informal caregiving on caregiver’s work-
place productivity. Workplace productivity of caregivers attending to patients (pts) 
with advanced renal cell cancer (advRCC) treated with temsirolimus (TEMSR) was 
compared with that of caregivers attending to pts treated with interferon-alfa (INFa). 
In addition, we evaluated the reaction of informal caregiving in both treatment groups. 
METHODS: Data were analyzed from phase 3 trial of pts with untreated, poor-
 prognosis advRCC. Pts were randomly assigned to 25 mg TEMSR weekly, or INFa 
(titrated to 18 mU) 3 times weekly. Caregiver work productivity and activity impair-
ment questionnaire (WPAI-CG), as well as a caregiver reaction assessment instrument 
(RAI), was administered at baseline and at 4-wk intervals until wk-32. Participation 
for caregiver study was on a voluntary basis. For the current analysis, we evaluated 
WPAI and RAI at pts’ last visits. ANCOVA model was used with baseline WPAI-CG, 
RAI, and measures of disease severity as covariates. RESULTS: Of 416 pts entered in 
the TEMSR (n  209) and IFNa (n  207) arms, data were available for 174 caregivers. 
About 50% of participating caregivers were employed (55% in TEMSR arm & 45% 
in INFa arm [p  0.1724]). Caring for advRCC pts was associated with substantial 
carer burden; on average, caregivers reported absenteeism of 11 hrs/wk and a 27% 
reduction in productivity at work. Caregivers caring for TEMSR pts reported signiﬁ-
cantly lower absenteeism (22% vs. 40%, p  0.0339), lower overall work productivity 
loss (34% vs. 49%, p  0.0178), and lower overall impairment in regular activity 
(29% vs. 38%, p  0.0305) than caregivers caring for INFa pts. Based on RAI ques-
tionnaire, caregivers of TEMSR pts reported a signiﬁcantly lower burden on their daily 
schedule compared with caregivers of INFa pts (14.0 vs. 15.9, p  0.0043). CONCLU-
SIONS: Although the study had 42% (174/416) caregiver participation rate, TEMSR 
therapy in advRCC is associated with reductions in caregiver burden.
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QUANTIFICATION TO ASSESS TARGETED TREATMENT EFFICACY: 
RESULTS OF A MULTI-CENTRIC PROSPECTIVE COST STUDY
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OBJECTIVES: The aim was to assess the cost of dynamic contrast -enhanced ultra-
sound (DCE -US) with quantiﬁcation of tumor perfusion parameters from raw linear 
data on a large sample of patients and tumors. METHODS: Eighteen French hospitals 
participated in the study. All consecutive exams performed to assess targeted treatment 
efﬁcacy were registered. The cost of each DCE -US was computed based on resource 
use data collected during the study: the duration of each exam, the type of staff and 
equipment and the amount of US contrast agent. To value resources we used unit 
costs at the Gustave-Roussy Institute. A sensitivity analysis was conducted. RESULTS: 
A total of 1452 DCE -US were recorded in 367 patients with mainly hepatocellular 
carcinoma (22%), or metastasis from kidney cancer (33%), colon cancer (12%) or 
melanoma (10%). Sorafenib, sunitinib and bevacizumab were the three most frequent 
treatments. The median number of DCE -US per patient was 5. Quantiﬁcation of 
perfusion parameters was possible in 881 DCE -US (62%). The mean duration of a 
DCE -US was 28 minutes. The radiologist’s intervention lasted 24 minutes on average. 
Quantiﬁcation of the tumor perfusion parameters lasted 17 minutes. The mean cost 
of a DCE -US was estimated at a173. In the sensitivity analysis, the cost ranged from 
a152a to a197. The cost of the baseline DCE -US was 10% higher than subsequent 
exams. A second bolus injection was required in 1/5 baseline exams to choose a rele-
vant target at treatment initiation. CONCLUSIONS: The cost of DCE -US is higher 
than conventional US mostly because of contrast agent use which accounts for half 
the cost of the procedure. Despite a 20% rate of re -injections and longer exams at 
baseline, the cost variability of DCE-US is rather low. This new technique strongly 
challenges CT perfusion in the monitoring of targeted treatments: it is cheaper and 
reduces the risk of radiation-related cancers.
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BREAST CANCER DIAGNOSTIC PROCESS: MANAGEMENT AND COST 
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OBJECTIVES: Organizational Analysis and Economic Evaluation of the Diagnostic 
process for breast cancer in Italian hospitals. METHODS: Multicenter, retrospective 
study involving 21 hospitals. Target population: patients whose diagnostic test results 
(ecography and/or mammography) and clinical examinations raised suspicion of 
malignancy and required further tests. Diagnostic procedures analysed: Cytological 
examination, Core Biopsy (CB), Vacuum-Assisted Breast Biopsy (VABB), on eco-
graphic and stereotactic guide, and Surgical biopsy. Based on the collected informa-
tion, a diagnosis path was built. Each path’s segment included a single procedure or 
a sequence of tests. Data on proportion of patients submitted to each path were col-
lected from centers enrolled. Resource use data including: time effort, consumables 
and technological supply. Unit costs were based on hospitals data and ofﬁcial tariffs 
(National Tariff Nomenclature for specialist services). Direct costs of the diagnostic 
process were determined from the hospital perspective. Cost of “Diagnostic Uncer-
tainty” was estimated considering further examinations needed. RESULTS: Data of 
29,457 patients were collected (about 15,000 patients/year). For the 45.8% of 
patients, radiologists choose the ecoguided cytological examination as ﬁrst exam; 
23.4% of patients with an ecovisible lesion performed a CB ecoguided; the 26.4% 
with no ecovisible lesion was subjected to a stereotactic VABB. Impact of further 
exams on the cost of diagnostic process increased the procedural costs by 356% for 
the ecoguided CB (a83 vs. a378) and the 36% of the stereoguided VABB cases (a683 
vs. a1.868). CONCLUSIONS: The most used procedures were CB and ecoguided 
cytological exam for ecovisible lesions and stereoguided VABB for non ecovisible 
lesions. Diagnostic path cost increased with respect to procedure cost, mostly relevant 
for CB, due to the use of surgical biopsy. The real economic impact is due, not only 
in direct costs of the exam itself, but also to those connected to the probability that 
others have to follow.
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OBJECTIVES: Chemotherapeutic drugs for mNSCLC patients are tested in “optimal 
conditions” in randomised control trials at prescribed dosing schedules. In clinical 
practice however, providers determine dosing schedules according to physician 
